Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
The Hungarian Investment Promotion Agency (HIPA) was established under a Government Decree to provide professional help to foreign companies intending to invest in Hungary. Our task is to support the implementation of the Government’s key investment promotion targets and to foster bilateral and multilateral international economic relations.
To this end, HIPA seeks and maintains contacts with potential foreign investors, helping them to prepare and implement strategic investment decisions, as well as providing post-decision support and encouraging their intention to re-invest. HIPA offers company and sector-specific consultancy, attends professional events, recommends locations, and organizes site visits. HIPA also acts as a mediator between large international companies and Hungarian firms to facilitate supplier relationships, organizing supplier training, and maintaining active contact with trade associations, particularly in the automotive and electronics sectors.
Our ultimate goal is to see Hungarian SMEs play as large a role as possible in the local multinational supply chain. We cooperate with government bodies involved in promoting investment, taking a dynamic role in preparing government decisions supporting priority investment projects, and in drafting proposals for the external economic aid scheme.
HIPA also supplies company-specific subsidy information on Hungarian and EU co-financed programmes and manages the EKD programme (investments supported by individual government decisions).
Contact
Tel: +36 1 872 6520
Fax: +36 1 872 6699
E-mail: info@hipa.hu
Web: www.hipa.hu
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it…
With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
Sanofi for 3,5 years. It must have been quite a different market, culture and environment. Yet, at that time you publicly announced that it only took you 30 seconds to…
See our Cookie Privacy Policy Here
